Scarica l'app Stockscreener
10.18
3.60%
-0.38
Pre-mercato:
10.56
0.38
+3.73%
Armata Pharmaceuticals Inc Borsa (ARMP) Ultime notizie
Update Recap: What analysts say about Armata Pharmaceuticals Inc stockEarnings Risk Report & Long-Term Safe Investment Plans - baoquankhu1.vn
Armata Pharmaceuticals, Inc. (TG1N.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
Armata Pharmaceuticals schedules annual meeting for June 11 - Investing.com
Armata Pharmaceuticals Sets Timeline for 2026 Annual Meeting - TipRanks
Armata Pharmaceuticals sets June 11, 2026 for annual stockholders meeting - TradingView
ARMP Technical Analysis & Stock Price Forecast - Intellectia AI
Market Outlook: Is Armata Pharmaceuticals Inc stock a smart retirement pick2026 Volume Leaders & Verified Swing Trading Watchlists - baoquankhu1.vn
Innoviva (INVA) files 10-K/A adding Armata audited financials and new officer certifications - stocktitan.net
Zenas Biopharma, Daqo New Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Armata Pharmaceuticals stock edges down on fourth quarter earnings miss By Investing.com - Investing.com Australia
Armata Pharmaceuticals stock edges down on fourth quarter earnings miss - Investing.com
Armata Pharmaceuticals Reports $173.8 Million Net Loss for 2025 Amid Convertible Loan Impact and Impairment Charges - Minichart
ARMP Reports Decrease in Grant Revenue for Q4 2025 - GuruFocus
Armata Pharmaceuticals: Advancing Bacteriophage Therapies for Antibiotic-Resistant Bacterial Infections in 2025 - Minichart
Armata Pharmaceuticals (ARMP) Q4 and Full-Year 2025 Earnings: Revenue Beat, Net Loss Hits $173.8M - Bayelsa Watch
Breakout Watch: Is Armata Pharmaceuticals Inc a cyclical or defensive stockPrice Action & AI Powered Market Trend Analysis - baoquankhu1.vn
ARMATA PHARMACEUTICALS, INC._December 31, 2025 - SEC.gov
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results - Finviz
Armata Pharmaceuticals (NASDAQ: ARMP) advances late-stage phage pipeline with new funding - Stock Titan
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
ARMP Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Armata Pharmaceuticals Reports Positive Phase 2a Study Results - MSN
HC Wainwright reaffirms buy on Armata Pharmaceuticals, Inc. (ARMP) after FDA nod - MSN
Armata Pharmaceuticals delays Q4 2025 results, gets FDA approval By Investing.com - Investing.com India
Armata Pharmaceuticals (ARMP) Delays Financial Results Release - GuruFocus
Armata Pharmaceuticals delays announcement of fourth quarter and full-year 2025 results and provides corporate update - marketscreener.com
Armata Pharmaceuticals delays Q4 2025 results, gets FDA approval - Investing.com
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update - Finviz
Armata Highlights AP-SA02 Progress Amid Earnings Release Delay - tipranks.com
Armata Pharmaceuticals delays 2025 results, wins QIDP and readies Phase 3 for AP-SA02 - TradingView
Armata Pharmaceuticals (ARMP) delays 2025 results, advances AP-SA02 toward Phase 3 - Stock Titan
Armata pushes back earnings as FDA backs Phase 3 staph blood infection study - Stock Titan
Armata Pharmaceuticals (ARMP) CBO reports tax-withheld share disposition - Stock Titan
Armata (ARMP) CEO Birx has 4,919 RSU shares withheld for tax obligations - Stock Titan
Pseudomonal Infections Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 10+ Leading Players Wheeling the Therapeutics Landscape - The Manila Times
Pseudomonal Infections Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 10+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Armata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags - Seeking Alpha
Armata Pharmaceuticals (ARMP) Projected to Post Earnings on Thursday - MarketBeat
Director at Armata (NASDAQ: ARMP) receives 25,640 stock options grant - Stock Titan
Armata (NASDAQ: ARMP) director receives 25,640 stock options at $11.61 strike - Stock Titan
[Form 4] Armata Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Armata Pharmaceuticals (ARMP) grants director 25,640 stock options - Stock Titan
Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update - GuruFocus
Published on: 2026-03-08 06:18:18 - baoquankhu1.vn
Will Armata Pharmaceuticals Inc. stock return to pre crisis levelsNew Guidance & Risk Controlled Swing Alerts - Naître et grandir
New Strong Sell Stocks for April 24th - MSN
Will Armata Pharmaceuticals Inc. stock outperform growth indexesQuarterly Portfolio Summary & Verified Technical Trade Signals - Naître et grandir
ARMPAmpliPhi Biosciences Announces Planned One-for-Ten Reverse Stock Split - mx.advfn.com
H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod - Yahoo Finance
Weekly Buzz: MGNX's LINNET Trial On Hold; ETON, ALUR Get FDA Nod; GILD Snaps Up ACLX - RTTNews
ARMP Should I Buy - Intellectia AI
Armata Pharmaceuticals (ARMP) Price Target Increased by 25.00% to 15.30 - Nasdaq
H.C. Wainwright lowers Armata Pharmaceuticals stock price target to $15 By Investing.com - Investing.com Canada
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):